You are here

  • Home
  • Archive
  • Volume 68, Issue Suppl 3
  • P230 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies

Article info

Article menu

Download PDFPDF

Inhaled therapy in COPD
P230 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies
Free

Authors

Citation

Koch A, Paggiaro P, Hamilton A, et al
P230 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies
Thorax 2013;68:A180-A181.

Publication history

  • First published November 14, 2013.
Online issue publication 
September 01, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions